Vascular Diseases
345
56
77
178
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
31 trials with published results (9%)
Research Maturity
178 completed trials (52% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.6%
16 terminated out of 345 trials
91.8%
+5.2% vs benchmark
14%
49 trials in Phase 3/4
17%
31 of 178 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 178 completed trials
Clinical Trials (345)
Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System
Natural History of Stroke: Cause and Development
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
Treatment With Aspirin After Preeclampsia: TAP Trial
CLOSM Trial: Groin Closure Using Layered Option for Suture Material
Optimal Blood Pressure Treatment Thresholds Postpartum
Thrombosis and Inflammation in Vessels Initiative (TIVI)
Gravity Stent-Retriever System For Reperfusion Of Large Vessel Occlusion Stroke Trial
Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)
SPYRAL GEMINI Pilot Study
Video Call Assisted Assessment of Acute Stroke
Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT
The Effects of Iontophoresed Vasoactive Drugs on Cutaneus Blood Flow
Comprehensive Management of High-risk PopuLatIon for Stroke Based on Social Network
Global Paradise System US Post Approval Study
Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Spyral InSight Study